Status:
COMPLETED
The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'
Lead Sponsor:
Addpharma Inc.
Conditions:
Gastric Ulcer
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.
Detailed Description
A randomized, open-label, single-dose, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of AD-115A and the administration of AD-1151 ...
Eligibility Criteria
Inclusion
- The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
- Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
Exclusion
- Individuals who have taken drugs that induce (e.g., barbiturates) or inhibit drug-metabolizing enzymes within 30 days prior to the start of the study (first dosing day), or have taken drugs that may affect this study within 10 days prior to the start of the study (first dosing day)
- Other exclusions applied
Key Trial Info
Start Date :
March 21 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 8 2025
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT06902818
Start Date
March 21 2025
End Date
May 8 2025
Last Update
October 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
H PLUS YANGJI HOSPITAL, Seoul,
Seoul, South Korea